GCP
CLRB icon

GSA Capital Partners’s Cellectar Biosciences CLRB Stock Holding History

GSA Capital Partners’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-992
Closed -$354K – 1475
2021
Q2 		$354K Buy
992
+470
+90% +$204K 0.04% 836
2021
Q1 		$252K Buy
+522
New +$310K 0.04% 756

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

GSA Capital Partners's CLRB Position: Q3 2021 in Review

GSA Capital Partners sold out of Cellectar Biosciences (CLRB) in Q3 2021, closing a stake of 992 shares — an estimated $354K sold.

GSA Capital Partners first reported a position in CLRB in Q1 2021 and held it in 2 quarters. The position peaked at $354K in Q2 2021. 38 funds tracked by Wall St. Rank hold CLRB as of Q3 2021.

  • GSA Capital Partners reported no remaining Cellectar Biosciences position as of Q3 2021 after selling out during the quarter.
  • GSA Capital Partners sold 992 Cellectar Biosciences shares in Q3 2021, an estimated $354K.
  • GSA Capital Partners first reported a position in Cellectar Biosciences in Q1 2021 and held it in 2 quarters.
  • GSA Capital Partners's Cellectar Biosciences position peaked at $354K in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2021.

Based on GSA Capital Partners's 13F filing for Q3 2021, filed 12 Nov 2021.